The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Vertex Pharmaceuticals

  • VRTX
  • NASDAQ
  • Consumer Products
  • Latest 92.13
  • Currency US$
  • Change -0.86
  • Percent Change -0.925 %
  • Volume 1,151,152
  • Mon Sep 15, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 92.81
  • Previous Close 92.99
  • High 92.81
  • Low 91.27
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High07/11 99.74
  • 52-week Low11/12 58.06
  • Beta 0.059
  • Market Cap 21,721.49M
  • EPS -2.03
  • P/E
  • Forward P/E 1,535.50
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $1,002,060,000
  • Earnings $-369,480,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $424,040,000
  • Current Ratio 3.83

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $2,197,100,000
  • Liabilities $966,230,000
  • Liabilities-to-Equity Ratio 0.78

Price Ratios

  • Price to Sales 21.68
  • Price to Book 17.65
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Jul 29 $-0.74 Nov 4 $-0.61
Surprises Jul 29 6.76% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Sep 15, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)

Related Securities
Symbol Type Latest % Chg

Officers

  • Jeffrey M. Leiden Chairman of the Board; Preside
  • Ian F. Smith Executive Vice President and C
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

50 NORTHERN AVENUE
BOSTON, MA
02210

Phone: (617)-341-6393
Fax: (617)-5762109

investorinfo@vrtx.com
www.vrtx.com

Ideas & Discussion

Live Discussion of VRTX on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.